Bridget Robinson

Q: What Schools Are Affiliated With Bridget Robinson

Bridget Robinson is affiliated with the following schools: University of Auckland, University of New Zealand, University of Western Australia, University of Liverpool, University of Sydney

Bridget Robinson's AcademicInfluence.com Rankings

Bridget Robinson

Medical

#1081

World Rank

#1379

Historical Rank

Oncology

#123

World Rank

#127

Historical Rank

medical Degrees

Download Badge

Medical

Bridget Robinson's Degrees

Bachelors Biomedical Science University of Auckland
Masters Cancer Biology University of New Zealand

Why Is Bridget Robinson Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Bridget Anne Robinson is a New Zealand oncology academic. As of 2018, she is a full professor at the University of Otago, holding the Mackenzie Chair since 2010. Academic career After a 1985 MD titled 'Effects of vasoactive agents on tumour blood flow and cytotoxic drug uptake' at the University of Otago, followed by a 1987 PhD of the same title, Robinson joined the staff in Christchurch in 1997, rising to full professor.

(See a Problem?)

Bridget Robinson's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. (2010) (380)
Moderate to heavy infections of Trichuris trichiura affect cognitive function in Jamaican school children (1992) (322)
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. (2014) (314)
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. (2016) (269)
MISMATCHED FAMILY DONORS FOR BONE-MARROW TRANSPLANTATION AS TREATMENT FOR ACUTE LEUKAEMIA (1983) (257)
The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP). (1983) (250)
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials (2017) (240)
The angiogenic switch for vascular endothelial growth factor (VEGF)‐A, VEGF‐B, VEGF‐C, and VEGF‐D in the adenoma–carcinoma sequence during colorectal cancer progression (2003) (238)
Carboplatin: a very active new cisplatin analog in the treatment of small cell lung cancer. (1985) (155)
Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. (2006) (152)
Clinical Pharmacokinetics and Dose Optimisation of Carboplatin (1997) (149)
Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C. (2012) (116)
Cisplatin/carboplatin cross-resistance in ovarian cancer. (1989) (116)
The short form of the alternatively spliced flt-4 but not its ligand vascular endothelial growth factor C is related to lymph node metastasis in human breast cancers. (2000) (113)
A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. (1991) (109)
A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717. (1986) (102)
Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel‐Lindau gene and hypoxia (2002) (97)
Cytomegalovirus and Epstein-Barr Virus in Breast Cancer (2015) (92)
An expanded universe of cancer targets (2021) (86)
Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia. (2001) (84)
Geohelminth infection and academic assessment in Jamaican children. (1991) (82)
Cancer disparities in indigenous Polynesian populations: Māori, Native Hawaiians, and Pacific people. (2008) (77)
Association of angiopoietin-2, C-reactive protein and markers of obesity and insulin resistance with survival outcome in colorectal cancer (2010) (70)
Optimizing transfection of primary human umbilical vein endothelial cells using commercially available chemical transfection reagents. (2010) (70)
Expression of vascular endothelial growth factor D is associated with hypoxia inducible factor (HIF-1α) and the HIF-1α target gene DEC1, but not lymph node metastasis in primary human breast carcinomas (2004) (66)
Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity. (2013) (65)
VEGF‐B expression in human primary breast cancers is associated with lymph node metastasis but not angiogenesis (2001) (62)
Increased Tumor Ascorbate is Associated with Extended Disease-Free Survival and Decreased Hypoxia-Inducible Factor-1 Activation in Human Colorectal Cancer (2014) (60)
Morbidity of cranial relapse in small cell lung cancer and the impact of radiation therapy. (1986) (59)
Angiopoietin-1 is inversely related to thymidine phosphorylase expression in human breast cancer, indicating a role in vascular remodeling. (2001) (58)
First and subsequent nonmelanoma skin cancers: incidence and predictors in a population of New Zealand renal transplant recipients. (2010) (56)
Hodgkin's cells express CD83, a dendritic cell lineage associated antigen (1997) (56)
Pharmacokinetic and anti-cancer properties of high dose ascorbate in solid tumours of ascorbate-dependent mice. (2016) (53)
Renal transplant recipients have elevated frequencies of circulating myeloid-derived suppressor cells. (2012) (51)
Activation of the hypoxia pathway in breast cancer tissue and patient survival are inversely associated with tumor ascorbate levels (2019) (45)
Caspase recruitment domain-containing protein 15 mutations in patients with colorectal cancer. (2006) (43)
Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5‐fluorouracil/leucovorin plus or minus oxaliplatin (2007) (42)
Restoring physiological levels of ascorbate slows tumor growth and moderates HIF-1 pathway activity in Gulo−/− mice (2014) (41)
Anti-vascular agent Combretastatin A-4-P modulates Hypoxia Inducible Factor-1 and gene expression (2006) (41)
Chemotherapy and irradiation in childhood Hodgkin's disease. (1984) (39)
Recurrent loss of heterozygosity correlates with clinical outcome in pancreatic neuroendocrine cancer (2017) (34)
Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer (2015) (33)
Expression of vascular endothelial growth factor D is associated with hypoxia inducible factor (HIF-1alpha) and the HIF-1alpha target gene DEC1, but not lymph node metastasis in primary human breast carcinomas. (2004) (32)
Fasting plasma lipid measurements following cisplatin chemotherapy in patients with germ cell tumors. (1992) (31)
Professional killer cell deficiencies and decreased survival in pulmonary arterial hypertension (2013) (31)
Responding to Acute Care Needs of Patients With Cancer: Recent Trends Across Continents. (2016) (31)
Childhood pica. Some aspects of the clinical profile in Manchester, Jamaica. (1990) (30)
Venous thromboembolism in cancer patients in Christchurch, 1995-1999. (2002) (29)
The Effect of Dihydropyrimidine Dehydrogenase Deficiency on Outcomes with Fluorouracil (2002) (28)
The Christchurch Tissue Bank to support cancer research. (2005) (28)
A sequential Bayesian algorithm for dose individualisation of carboplatin (1997) (27)
Phosphohistone H3 outperforms Ki67 as a marker of outcome for breast cancer patients (2015) (26)
Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies (2018) (24)
Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies (2018) (24)
Cytokeratin KRT8/18 expression differentiates distinct subtypes of grade 3 invasive ductal carcinoma of the breast. (2007) (23)
The Christchurch Breast Cancer Patient Register: the first year. (2012) (22)
Evaluation of xylazine in camels. (1980) (22)
Improved survival for rectal cancer compared to colon cancer: the four cohort study (2018) (21)
Comparison of methods of assessment of renal function in patients with cancer treated with cisplatin, carboplatin or methotrexate. (1990) (21)
Verapamil potentiation of melphalan cytotoxicity and cellular uptake in murine fibrosarcoma and bone marrow. (1985) (21)
The Association Between Ascorbate and the Hypoxia-Inducible Factors in Human Renal Cell Carcinoma Requires a Functional Von Hippel-Lindau Protein (2018) (20)
Ascorbate modulates the hypoxic pathway by increasing intracellular activity of the HIF hydroxylases in renal cell carcinoma cells (2019) (19)
Breast cancer and cytomegalovirus (2019) (19)
Ondansetron antiemetic therapy for chemotherapy and radiotherapy induced vomiting in children. (1992) (19)
Identification of a novel PTEN mutation (L139X) in a patient with Cowden disease and Sjögren's syndrome. (1998) (19)
Adherence to Adjuvant Endocrine Therapy in Christchurch Women with Early Breast Cancer. (2018) (18)
Angiogenesis and host immune response contribute to the aggressive character of non‐melanoma skin cancers in renal transplant recipients (2011) (18)
Clinical implications of the genetics of sporadic colorectal cancer (2019) (17)
Effect of post-implant exercise on tumour growth rate, perfusion and hypoxia in mice (2020) (17)
Outcomes for Patients with Non-metastatic Triple-negative Breast Cancer in New Zealand. (2019) (17)
Vitamin C Administration by Intravenous Infusion Increases Tumor Ascorbate Content in Patients With Colon Cancer: A Clinical Intervention Study (2020) (16)
Marginal effects of glucose, insulin and insulin-like growth factor on chemotherapy response in endothelial and colorectal cancer cells (2013) (16)
Pharmacokinetics and efficacy of rectal versus oral sustained-release morphine in cancer patients (2004) (16)
Second malignant neoplasms in patients with Hodgkin's disease. (1994) (15)
Hypofractionated radiation treatment following mastectomy in early breast cancer: The Christchurch experience (2015) (15)
International multi-centre randomised Phase II/III study of Capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for metastatic colorectal cancer (mCRC): Final safety analysis of the AGITG MAX trial (2008) (14)
A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer (2011) (14)
Epidermal growth factor (hEGF) has no effect on murine intestine epithelial damage and regeneration after melphalan. (1985) (12)
High-dose cyclophosphamide with autologous bone marrow rescue after conventional chemotherapy in the treatment of small cell lung carcinoma (2004) (11)
Ischaemic heart disease following conventional and hypofractionated radiation treatment in a contemporary breast cancer series (2018) (11)
Colorectal multidisciplinary meeting audit to determine patient benefit (2017) (11)
Association of chromosome band 8q22 copy number gain with high grade invasive breast carcinomas by assessment of core needle biopsies (2008) (10)
A risk factor for relapse in Hodgkin's disease: Female gender? (1989) (10)
Dual-Color Fluorescence In Situ Hybridization Reveals an Association of Chromosome 8q22 but Not 8p21 Imbalance with High Grade Invasive Breast Carcinoma (2013) (10)
Low Vitamin C Status in Patients with Cancer Is Associated with Patient and Tumor Characteristics (2020) (10)
Colorectal cancer treated at Christchurch Hospital, New Zealand: a comparison of 1993 and 1998 cohorts. (2005) (9)
A workforce survey of New Zealand medical oncologists. (2013) (9)
Circadian pharmacokinetics of methotrexate (2004) (8)
Effects of verapamil and alcohol on blood flow, melphalan uptake and cytotoxicity, in murine fibrosarcomas and human melanoma xenografts. (1986) (8)
Meeting the challenges of interpreting variants of unknown clinical significance in BRCA testing. (2015) (7)
30‐day mortality following palliative radiotherapy (2020) (7)
Consumption of vitamin C is below recommended daily intake in many cancer patients and healthy volunteers in Christchurch. (2014) (7)
HEMORRHAGIC LYMPHADENOPATHY AS A PRESENTING FEATURE OF PRIMARY AL AMYLOIDOSIS (2000) (7)
Body mass index (BMI): association with clinicopathological factors and outcome of women with newly diagnosed breast cancer in New Zealand. (2017) (7)
Body mass index and outcomes in breast cancer treated with breast conservation. (2020) (7)
Investigation of Experimental Factors That Underlie BRCA1/2 mRNA Isoform Expression Variation: Recommendations for Utilizing Targeted RNA Sequencing to Evaluate Potential Spliceogenic Variants (2018) (7)
A profile of prognostic and molecular factors in European and Māori breast cancer patients (2010) (7)
Characterisation of enzyme prodrug gene therapy combinations in coated spheroids and vascular networks in vitro (2012) (6)
Adriamycin cardiotoxicity monitoring by radionuclide scan. (1983) (5)
6001 International randomised phase III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) in first line treatment of metastatic colorectal cancer (mCRC): final results of the AGITG MAX trial (2009) (5)
Baroreflex failure secondary to paraneoplastic encephalomyelitis in a 17 year old woman with neuroblastoma (2004) (5)
Influence of serum inflammatory cytokines on cytochrome P450 drug metabolising activity during breast cancer chemotherapy: a patient feasibility study (2021) (4)
Radiation treatment in early stage triple‐negative breast cancer in New Zealand: A national database study (2019) (4)
Effects of Exercise and Anti-PD-1 on the Tumour Microenvironment. (2021) (4)
Correlation of PI3KCA and extended RAS gene mutation status with outcomes from the phase III AGITG MAX involving capecitabine (C) alone or in combination with bevacizumab (B) with or without mitomycin C (M) in advanced colorectal cancer (CRC). (2014) (4)
Expression of vascular endothelial growth factor D is associated with hypoxia inducible factor ( HIF-1 a ) and the HIF-1 a target gene DEC 1 , but not lymph node metastasis in primary human breast carcinomas (2004) (4)
Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study (2014) (4)
Comparing utilities for advanced colorectal cancer valued from societal and cancer patients' perspectives using baseline data from the MAX study (2008) (3)
High‐grade Glioma – A decade of care in Christchurch (2019) (3)
Continued progress with stage III colorectal cancer--a triple cohort study. (2013) (3)
Hypofractionated radiation treatment in early breast cancer: Results in a New Zealand setting (2016) (2)
Limited Association Between Ascorbate Concentrations and Vitamin C Transporters in Renal Cell Carcinoma Cells and Clinical Samples. (2021) (2)
Is the Immunogenicity of PD-1 Blocking Antibodies a Confounding Variable in Murine Studies? (2021) (2)
Complications of curative radiation treatment for early prostate cancer (2018) (2)
A review of the Christchurch Hospital Breast Cancer Service in 2012: meeting the new Tumour Standards. (2014) (2)
Geriatric subgroup of AGITG MAX trial: International randomized phase III trial of capecitabine (C), bevacizumab (B), and mitomycin C (M) in first-line metastatic colorectal cancer (CRC). (2011) (2)
Cancer of unknown primary site. (1988) (1)
Increased Ascorbate Content of Glioblastoma Is Associated With a Suppressed Hypoxic Response and Improved Patient Survival (2022) (1)
Neutropenic sepsis complicating treatment of solid tumours, lymphoma and myeloma. (1992) (1)
Tumour growth in mice resistant to diet-induced obesity (2015) (1)
Chemotherapy andirradiation inchildhood Hodgkin's disease (1984) (1)
Quantifying BRCA1 and BRCA2 mRNA Isoform Expression Levels in Single Cells (2019) (1)
Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers (2022) (1)
EARLY CLINICAL-STUDIES WITH CB3717 ((N-(4-(N-(2-AMINO-4-HYDROXY-6-QUINAZOLINYL)METHYL)PROP-2-YNYLAMINO)BENZOYL)-L-GLUTAMIC ACID (1984) (1)
Control of emesis associated with cancer chemotherapy. (1993) (1)
Long‐term results from a series of patients managed with breast conservation surgery and hypofractionated radiotherapy in Christchurch: What is the recurrence rate and how do we detect recurrences (2020) (1)
The management of small cell lung cancer in Christchurch 1979-89. (1991) (1)
Care of Seniors with Breast Cancer - Treatment Received and Refining Decision Making. (2022) (1)
Treatment of BRAF V600E mutated ganglioglioma of the third ventricle with dabrafenib (2021) (1)
Cancer services to 2025 in New Zealand--investing in research-driven quality care. (2014) (1)
O-019SIRFLOX: Randomized trial comparing first-line mFOLFOX6 ± bevacizumab versus mFOLFOX6 + selective internal radiation therapy (SIRT) ± bevacizumab in patients with metastatic colorectal cancer (mCRC) – analysis by presence or absence of extra-hepatic metastases and bevacizumab treatment (2015) (1)
SIRFLOX: Differences in site of first progression between mFOLFOX6 +/- bevacizumab (bev) versus mFOLFOX6 +/- bev plus selective internal radiation therapy (SIRT) in first-line patients (pts) with metastatic colorectal cancer (mCRC). (2016) (0)
Adjuvant nodal field radiation in resected Stage III melanoma: A single‐centre retrospective study in Christchurch, New Zealand (2022) (0)
Outcome and dose intensity (DI) in the elderly subgroup of the AGITG MAX phase III trial of capecitabine (C), bevacizumab (B), and mitomycin C (M) in first-line metastatic colorectal cancer (CRC). (2011) (0)
Autologous bone marrow rescue is unnecessary after high-dose cyclophosphamide (7 g/m2) (1984) (0)
The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer (2019) (0)
High grade nonHodgkin's lymphoma: management with moderate dose combination chemotherapy. (1988) (0)
Activation of the hypoxia pathway in breast cancer tissue and patient survival are inversely associated with tumor ascorbate levels (2019) (0)
PHASE-I CLINICAL-TRIAL OF CB3717 ((N-(4-(N-((2-AMINO-4-HYDROXY-6-QUINAZOLINYL)METHYL)PROP-2-YNYLAMINO)BENZOYL)-L-GLUTAMIC ACID) (1984) (0)
Survival of transplanted and dialysed patients in a French region with focus on outcomes in the elderly (2009) (0)
High-Dose Ascorbate Administration Increases Tumor Ascorbate Levels and Decreases Hypoxia-Inducible Factor-1 Activity and Tumor Growth in Mice (2016) (0)
SO01 NEOADJUVANT: RECTAL CANCER (2007) (0)
Serum profiles and safety of intermediate-dose (500–1,000 mg) methotrexate following IV and IM administration (2004) (0)
P16.11 Vitamin C levels and the hypoxic pathway in human glioma tissues (2021) (0)
Recurrent loss of heterozygosity correlates with clinical outcome in pancreatic neuroendocrine cancer (2018) (0)
P12.03.B Ascorbate alters the hypoxic pathway in glioblastoma cellsin vitro and associates with improved patient survival (2022) (0)
Abstract 229: Restoring physiological levels of ascorbate alleviates HIF-1 activation and reduces tumour growth in Gulo-/- mice (2014) (0)
Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study (2014) (0)
The management of recurrent and metastatic colorectal adenocarcinoma. (1998) (0)
Short report Identification of a novel PTEN mutation (L139X) in a patient with Cowden disease and Sjögren’s syndrome (1998) (0)
Frailty in Older Patients Referred to Oncology, and Impact of Treatment: Use of a Modified 6 Item Score (2019) (0)
Effect of immune modulation on the skeletal muscle mitochondrial exercise response: An exploratory study in mice with cancer (2021) (0)
Expression of HIF-la in human tumours. Authors' reply (2005) (0)
The impact of coding germline variants on contralateral breast cancer risk and survival (2023) (0)
PR13 INCIDENCE AND SUBSEQUENT NON‐MELANOMA SKIN CANCERS IN CANTERBURY RENAL TRANSPLANT RECIPIENTS –WHAT CAN WE LEARN? (2009) (0)
Cancer trials in New Zealand--patients are not the problem. (2013) (0)
Clinical leadership in control of melanoma. (1994) (0)
Under-ascertainment of breast cancer susceptibility gene carriers in a cohort of New Zealand female breast cancer patients (2020) (0)
Ascorbate content of clinical glioma tissues is related to tumour grade and to global levels of 5-hydroxymethyl cytosine (2022) (0)
P12.06.A Relationship between ascorbate and DNA methylation markers in clinical glioma tumours (2022) (0)

This paper list is powered by the following services:

Other Resources About Bridget Robinson

en.wikipedia.org

What Schools Are Affiliated With Bridget Robinson?

Bridget Robinson is affiliated with the following schools:

Bridget Robinson's Academic­Influence.com Rankings